Condition category
Urological and Genital Diseases
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
Chronic kidney disease (CKD) is a long-term condition where the kidneys do not work properly. In a healthy person, the kidneys are responsible for filtering out the waste products and excess water in the blood, and converting them into urine. In patients suffering from CKD, the kidneys are unable to do this, and so the body is unable to get rid of the waste products building up in the blood. Haemodialysis is one of the most common treatments for CKD patients, and involves diverting the blood into an external machine so that it can be “cleaned”, before being returned to the body. It requires direct access to the circulatory system (blood stream) and the best option for this is a by creating an arterio-venous fistula (AVF), which is made by surgically joining an artery and a vein in the arm. AVFs have a limited lifespan, and over time can become narrowed (stenosed) or blocked (thrombosed). The fistula can be used for haemodialysis again if it is “re-opened”. This is done by inflating a small balloon inside the fistula to flatten any blockages against the artery wall (fistuloplasty). In many cases however, the fistula re-narrows and becomes blocked again (restenosis). New techniques have been developed where the balloon used in the fistuloplasty is coated in a drug, such as Paclitaxel (drug-eluting balloon, DEB). This drug slows the growth of new smooth muscle cells in the vessel wall that may lead to re-narrowing (restenosis). The aim of this study is to find out whether a DEB is more effective than standard balloons (with no drug coating) at slowing down and preventing restenosis.

Who can participate?
Adults who have a narrowed AVF, which has been in use for at least 1 month.

What does the study involve?
Participants are randomly allocated to one of two groups. Participants in the first group receive the standard fistuloplasty procedure, in which a plain balloon is inflated until the fistula becomes wide enough to become usable. Participants in the second group receive the standard fistuloplasty procedure, in which a balloon coated in a drug called paclitaxel is used. Participants attend follow-up appointments 3, 6 and 12 months after their operation so that the openness (patency) of the fistula can be monitored.

What are the possible benefits and risks of participating?
Not provided at time of registration

Where is the study run from?
Queen Elizabeth Hospital, Birmingham (UK)

When is the study starting and how long is it expected to run for?
January 2016 to October 2018

Who is funding the study?
Boston Scientific Corporation (USA)

Who is the main contact?
Mrs Nicola Anderson

Trial website

Contact information



Primary contact

Mrs Nicola Anderson


Contact details

Renal Research Team
Queen Elizabeth Hospital
Mindelsohn Way
B15 2TH
United Kingdom

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

Improving outcomes in fistula intervention: A prospective, patient blinded, phase III, randomised controlled trial of drug eluting balloons in the angioplasty of native haemodialysis access arterio-venous fistula outflow stenosis



Study hypothesis

The aim of this study is to investigate whether the use of drug eluting balloons (DEB's) during angioplasty can reliably reduce the rate of re­stenosis.

Ethics approval

First Medical Research Ethics Committee, 05/11/2015, ref: 15/EM/0483

Study design

Randomised; Interventional; Design type: Treatment

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details to request a patient information sheet


Renal failure


Participants are randomised into one of two arms.

Intervention arm: Participants receive a fistuloplasty procedure using a paclitaxel-coated balloon.
Control arm: Participants receive a fistuloplasty procedure using an un-coated balloon.

Participants in both groups are followed up at 3, 6 and 12 months post-fisuloplasty.

Intervention type



Phase III

Drug names

Primary outcome measure

Presence of at least 50% restenosis of index lesion requiring re-intervention is measured at 3, 6 and 12 months.

Secondary outcome measures

1. Fistula failure rate (thrombosis or non-salvageable) is measured at 3, 6 and 12 months
2. Re-intervention rate due to clinical or paraclinical indictions (without 50% restenosis) is measured at 3, 6 and 12 months

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Arteriovenous (AV) fistulas with stenosis requiring percutaneous angioplasty identified on routine diagnostic imaging or causing clinical concern on dialysis
2. Fistula has been in use for at least 1 month and is more than 6 weeks old
3. Brachiocephalic AV fistula
4. Brachiobasilic AV fistula
5. Radiocephalic AV fistula (both proximal and distal)
6. Aged 18 years or over
7. Index lesion is less then the length of the DEB, and the reference vessel diameter is appropriate for treatment with the size range of DEB (4mm ­ 8mm diameter)
8. Capacity to give valid informed consent

Participant type


Age group




Target number of participants

Planned Sample Size: 186; UK Sample Size: 186

Total final enrolment


Participant exclusion criteria

1. Allergy to iodinated Intravenous contrast
2. Allergy to Paclitaxel
3. Prosthetic grafts
4. Long or tandem lesions that cannot be treated with a single DEB
5. Thrombosed Arterio­Venous fistulas
6. Women who are breastfeeding, pregnant or intending to become pregnant
7. Participants of child­bearing age who are unwilling to use a reliable form of contraception for the duration of the study

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Queen Elizabeth Hospital
Mindelsohn Way Edgbaston
B15 2TH
United Kingdom

Sponsor information


University Hospital Birmingham NHS Foundation Trust

Sponsor details

Renal Department
Queen Elizabeth Hospital
B15 2TH
United Kingdom

Sponsor type

Hospital/treatment centre



Funder type


Funder name

Boston Scientific Corporation

Alternative name(s)

Boston Scientific, Boston Scientific Corp., BSC

Funding Body Type

private sector organisation

Funding Body Subtype

For-profit companies (industry)


United States of America

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal.

IPD sharing statement: The data sharing plans for the current study are unknown and will be made available at a later date.

Intention to publish date


Participant level data

To be made available at a later date

Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes

22/05/2020: Total final enrolment number added. 08/05/2019: Internal review. 02/04/2019: The condition has been changed from "Topic: Renal disorders; Subtopic: Renal disorders; Disease: All Renal disorders" to "Renal failure" following a request from the NIHR. 21/11/2018: The following changes were made: 1. The publication and dissemination plan was added. 2. The participant level data was added. 07/11/2018: The following changes were made: 1. The recruitment end date was changed from 29/10/2018 to 30/04/2019. 2. The overall trial end date was changed from 29/10/2018 to 30/04/2020. 3. The intention to publish date was changed from 29/10/2019 to 30/04/2021. 31/10/2017: Internal review.